Related Experiment Video
Updated: Aug 19, 2026

Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
Published on: June 3, 2022
Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass
Haven Baker1, Vyomesh Patel, Alfredo A Molinolo
1Chemistry and Chemical Biology Department, Barnett Institute, Northeastern University, 341 Mugar Building, 360 Huntington Avenue, Boston, MA 02115, USA.
Abstract:
Remarkable progress has been made to identify genes expressed in squamous cell carcinomas of the head and neck (HNSCC). However, limited information is available on their corresponding protein products, whose expression, post-translational modifications, and activity are ultimately responsible for the malignant behavior of this tumor type. We have combined laser-capture microdissection (LCM) with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify proteins expressed in histologically normal squamous epithelium and matching SCC. The protein fraction from approximately 10,000-15,000 normal and tumor cells was solubilized, digested with trypsin, and the resulting peptides were analyzed by LC-MS/MS. Database searching of the resulting sequence information identified 30-55 proteins per sample. Keratins were the most abundant proteins in both normal and tumor tissues. Among the proteins differentially expressed, keratin 13 was much lower in tumors, whereas heat-shock (Hsp) family members were highly expressed in neoplastic cells. Wnt-6 and Wnt-14 were identified in both normal and tumor tissues, respectively, and placental growth factor (PIGF) was detected only in tumors. Immunohistochemical analysis of HNSCC tissues revealed lack of keratin 13 in tumor tissues, and strong staining in normal epithelia, and high expression of Hsp90 in tumors. Our study, by combining LCM and proteomic technologies, underscores the advantages of this approach to investigate complex changes at the protein level in HNSCC, thus complementing existing and emerging genomic technologies. These efforts may likely result in the identification of new biomarkers for HNSCC that can be used to diagnose disease, predict susceptibility, and monitor progression in individual patients.
Insights
Researchers identified key proteins in head and neck squamous cell carcinomas (HNSCC) using advanced proteomic techniques. This study reveals differential protein expression, offering potential new biomarkers for HNSCC diagnosis and progression monitoring.
Area of Science:
- Proteomics
- Oncology
- Molecular Biology
Background:
- Gene expression studies in head and neck squamous cell carcinomas (HNSCC) are advancing, but protein-level data remains limited.
- Understanding protein expression, modifications, and activity is crucial for explaining HNSCC's malignant behavior.
Purpose of the Study:
- To identify and compare proteins in normal squamous epithelium and HNSCC using a combined proteomic approach.
- To investigate differential protein expression and discover potential biomarkers for HNSCC.
Main Methods:
- Combined laser-capture microdissection (LCM) with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze protein fractions.
- Analyzed protein samples from approximately 10,000-15,000 normal and tumor cells.
- Utilized database searching to identify proteins and immunohistochemistry to validate findings.
Main Results:
- Identified 30-55 proteins per sample, with keratins being the most abundant in both normal and tumor tissues.
- Observed lower expression of keratin 13 in tumors compared to normal tissues.
- Found elevated expression of heat-shock (Hsp) family members, specifically Hsp90, in HNSCC tumors.
- Detected Wnt-6, Wnt-14, and placental growth factor (PIGF) differentially in normal and tumor tissues.
Conclusions:
- The combined LCM and proteomic approach effectively investigates protein-level changes in HNSCC.
- Differential protein expression, such as keratin 13 and Hsp90, highlights potential diagnostic and prognostic biomarkers.
- This proteomic strategy complements genomic technologies and may lead to novel HNSCC biomarkers for clinical applications.

